{"id":2332,"date":"2024-03-05T11:29:36","date_gmt":"2024-03-05T16:29:36","guid":{"rendered":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/?post_type=ud_entry&p=2332"},"modified":"2026-04-09T10:27:11","modified_gmt":"2026-04-09T14:27:11","slug":"geetha-boligala","status":"publish","type":"ud_entry","link":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/","title":{"rendered":"Geetha Boligala"},"content":{"rendered":"

Research:\u00a0<\/strong>Tumor-immune regulation by Dishevelled (DVL) proteins in triple-negative breast cancer (TNBC)
\nArea of Focus : <\/b>Tumor immunology and Wnt signaling<\/p>\n

 <\/p>\n

\"Geetha<\/a>
Figure 1:<\/b> Schematic representation of the proposed role of DVL2 in regulating the tumor immune microenvironment. Loss of DVL2 is proposed to enhance tumor immunogenicity through increased MHC-I antigen presentation and the induction of pro-inflammatory signals. Figure 2:<\/b> Experimental workflow for in vivo tumor studies. Control and DVL- deficient tumor cells were orthotopically injected into mice and tumor growth was monitored over time. At endpoints, tumors and relevant tissues were harvested for downstream analyses, to evaluate the tumor immune microenvironment. Figure 3:<\/b> Functional model of DVL2 knockout tumors. Loss of DVL2 promotes CD8\u207a T- cell infiltration and activation resulting in cytotoxic T cell mediated tumor cell apoptosis.<\/figcaption><\/figure>\n

Open Questions<\/b><\/p>\n

    \n
  • Does DVL2 suppress tumor immunogenicity via MHC-I regulation?<\/li>\n
  • What signaling pathways drive immune cell recruitment upon DVL2 loss?<\/li>\n
  • Is the anti-tumor effect of DVL2 loss CD8\u207a T-cell dependent?<\/li>\n
  • How does DVL2 loss reprogram the tumor immune microenvironment?<\/li>\n<\/ul>\n

     <\/p>\n","protected":false},"featured_media":2309,"menu_order":0,"template":"","format":"standard","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","_links_to":"","_links_to_target":""},"ud_division":[6],"class_list":["post-2332","ud_entry","type-ud_entry","status-publish","format-standard","has-post-thumbnail","hentry","ud_division-postdoc-res","odd"],"acf":[],"ud_entry_custom_fields":{"ud_last_name":"Boligala","ud_first_name":"Geetha","ud_gallery_summary":"

    Research Interests<\/b>: <\/strong>Tumor-immune regulation by Dishevelled (DVL) proteins in triple-negative breast cancer (TNBC)
    \nArea of Focus<\/b>: <\/strong>Tumor immunology and Wnt signaling<\/p>\n","ud_telephone":false,"ud_email":"Geetha_Boligala@med.unc.edu","ud_positions":[{"ud_title":"Postdoctoral Researcher"}],"ud_options":[],"ud_sort_order":""},"featured_image":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3.jpg","featured_image_medium":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3-300x300.jpg","featured_image_medium_large":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3.jpg","featured_image_large":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3.jpg","featured_image_thumbnail":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3-150x150.jpg","yoast_head":"\nGeetha Boligala - Pruitt Lab<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Geetha Boligala - Pruitt Lab\" \/>\n<meta property=\"og:description\" content=\"Research:\u00a0Tumor-immune regulation by Dishevelled (DVL) proteins in triple-negative breast cancer (TNBC) Area of Focus : Tumor immunology and Wnt signaling   Open Questions Does DVL2 suppress tumor immunogenicity via MHC-I regulation? What signaling pathways drive immune cell recruitment upon DVL2 loss? Is the anti-tumor effect of DVL2 loss CD8\u207a T-cell dependent? How does DVL2 loss … Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/\" \/>\n<meta property=\"og:site_name\" content=\"Pruitt Lab\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-09T14:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/\",\"url\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/\",\"name\":\"Geetha Boligala - Pruitt Lab\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3.jpg\",\"datePublished\":\"2024-03-05T16:29:36+00:00\",\"dateModified\":\"2026-04-09T14:27:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/#primaryimage\",\"url\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3.jpg\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3.jpg\",\"width\":400,\"height\":400,\"caption\":\"Geetha Boligala\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Directory Entries\",\"item\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Geetha Boligala\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/\",\"name\":\"Pruitt Lab\",\"description\":\"Department of Pharmacology\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Geetha Boligala - Pruitt Lab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/","og_locale":"en_US","og_type":"article","og_title":"Geetha Boligala - Pruitt Lab","og_description":"Research:\u00a0Tumor-immune regulation by Dishevelled (DVL) proteins in triple-negative breast cancer (TNBC) Area of Focus : Tumor immunology and Wnt signaling   Open Questions Does DVL2 suppress tumor immunogenicity via MHC-I regulation? What signaling pathways drive immune cell recruitment upon DVL2 loss? Is the anti-tumor effect of DVL2 loss CD8\u207a T-cell dependent? How does DVL2 loss … Read more","og_url":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/","og_site_name":"Pruitt Lab","article_modified_time":"2026-04-09T14:27:11+00:00","og_image":[{"width":400,"height":400,"url":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/","url":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/","name":"Geetha Boligala - Pruitt Lab","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/#primaryimage"},"image":{"@id":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3.jpg","datePublished":"2024-03-05T16:29:36+00:00","dateModified":"2026-04-09T14:27:11+00:00","breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/#primaryimage","url":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3.jpg","contentUrl":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-content\/uploads\/sites\/1395\/2024\/03\/GPB-400-3.jpg","width":400,"height":400,"caption":"Geetha Boligala"},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/geetha-boligala\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/"},{"@type":"ListItem","position":2,"name":"Directory Entries","item":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/people\/"},{"@type":"ListItem","position":3,"name":"Geetha Boligala"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/#website","url":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/","name":"Pruitt Lab","description":"Department of Pharmacology","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-json\/wp\/v2\/ud_entry\/2332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-json\/wp\/v2\/ud_entry"}],"about":[{"href":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-json\/wp\/v2\/types\/ud_entry"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-json\/wp\/v2\/media\/2309"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-json\/wp\/v2\/media?parent=2332"}],"wp:term":[{"taxonomy":"ud_division","embeddable":true,"href":"https:\/\/www.med.unc.edu\/pharm\/pruittlab\/wp-json\/wp\/v2\/ud_division?post=2332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}